Study guide

Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis

Key Takeaways Explain This Topic AI

Anaphylaxis is a clinical diagnosis and may occur without skin signs. Consider rapid respiratory or circulatory compromise after an allergen exposure; WAO 2020 includes acute bronchospasm or laryngeal involvement after a known or highly probable trigger even without rash.

Intramuscular adrenaline (epinephrine 1:1,000, 1 mg/mL) dosed at 10 micrograms/kg (0.01 mg/kg, maximum single dose 0.5 mg) into the anterolateral mid-thigh is the non-negotiable first-line treatment, repeatable every 5 minutes.

Keep a patient with circulatory instability flat, with legs raised if tolerated. Predominant breathing difficulty may require a semi-recumbent position; use the recovery position if unconscious and breathing. Do not let the patient stand, walk or sit up suddenly.

Second-line therapies, including H1-antihistamines and systemic corticosteroids, never treat upper airway edema or circulatory shock and must never delay prompt, repeated intramuscular adrenaline administration.

Persistent respiratory or circulatory compromise after two appropriate IM adrenaline doses requires urgent expert help, fluids and a titrated IV adrenaline infusion (typically 0.05–0.1 microgram/kg/min initially). Continue IM doses every 5 minutes until an infusion can safely start; do not wait for PICU transfer or an arterial line.

Last updated: November 2026

Paediatric Anaphylaxis: Clinical Recognition, Pharmacotherapy, and Emergency Resuscitation

Anaphylaxis is an acute, potentially fatal systemic hypersensitivity reaction characterized by rapid onset of life-threatening airway, breathing, or circulatory problems. In children, food allergens—predominantly peanut, tree nuts, cow's milk, hen's egg, fish, and shellfish—represent the most frequent triggers, followed by venom stings (Hymenoptera) and medications (e.g., beta-lactam antibiotics and neuromuscular blocking agents). Prompt recognition and immediate administration of intramuscular adrenaline form the foundation of successful emergency management.

Diagnostic Criteria: WAO / EAACI Consensus Guidelines

EAACI 2021 retains the following three NIAID/FAAN clinical patterns . WAO 2020 uses two patterns: acute skin/mucosal involvement plus respiratory compromise, reduced BP or severe gastrointestinal symptoms (especially after non-food triggers); or acute hypotension, bronchospasm or laryngeal involvement after a known/highly probable allergen, even without skin signs. This latter bronchospasm criterion excludes isolated lower-airway symptoms from common inhalant allergens or perceived food-inhalation reactions without ingestion. Do not wait for a rash before treating life-threatening anaphylaxis.

The three EAACI patterns are:

Presentation 1: Acute Multiorgan Presentation with Skin/Mucosal Involvement

Acute onset (within minutes to several hours) of symptoms involving the skin, mucosal tissue, or both (e.g., generalized urticaria, intense pruritus, flushing, swollen lips, tongue, or uvula),

AND AT LEAST ONE OF THE FOLLOWING:

Respiratory compromise : Dyspnoea, tachypnoea, wheezing, bronchospasm, stridor, reduced peak expiratory flow, or hypoxaemia.

Reduced blood pressure or end-organ dysfunction : Hypotension (age-specific criteria), hypotonia, syncope, incontinence, or marked diaphoresis.

Presentation 2: Rapid Multiorgan Reaction to a Likely Allergen

Two or more of the following occurring rapidly (within minutes to several hours) after exposure to a likely allergen for that specific patient:

Sudden involvement of the skin or mucosal tissues (urticaria, itch, flushing, angioedema).

Respiratory compromise (dyspnoea, wheeze, stridor, hypoxaemia).

Reduced blood pressure or associated symptoms of end-organ hypoperfusion (collapse, syncope).

Persistent gastrointestinal symptoms : Severe crampy abdominal pain, repetitive projectile vomiting (particularly common in food-triggered paediatric anaphylaxis).

Presentation 3: Hypotension Following Known Allergen Exposure

Reduced blood pressure occurring rapidly after exposure to a known allergen for that specific patient:

Infants and children : Low systolic blood pressure (age-specific 5th percentile) or a > 30 % >30\% > 30% decrease from baseline systolic blood pressure.

Adolescents and adults : Systolic blood pressure < 90 mmHg <90\text{ mmHg} < 90 mmHg or a > 30 % >30\% > 30% decrease from baseline.

Important

Cutaneous manifestations (urticaria, erythema, angioedema) are absent in 10 % to 20 % 10\%\text{ to }20\% 10% to 20% of paediatric anaphylaxis presentations. The absence of a rash does not exclude anaphylaxis, especially in rapid cardiovascular collapse following intravenous medication delivery or insect venom inoculation.

  • Cellular Pathophysiology and Vascular Collapse
  • Classic anaphylaxis is a Type I IgE-mediated hypersensitivity reaction: [Allergen Re-exposure]
  • |
  • v
  • [Cross-linking of Specific IgE on FcεRI Receptors]
  • |
  • v
  • [Explosive Degranulation of Mast Cells & Basophils]
  • / \
  • [Preformed Granule Mediators] [Newly Synthesized Lipid Mediators]
  • Histamine (H1, H2) - Leukotrienes (LTC4, LTD4, LTE4)
  • Neutral Proteases (Tryptase) - Prostaglandin D2 (PGD2)
  • Heparin, Proteoglycans - Platelet-Activating Factor (PAF)
  • \ /
  • +--------------------+----------------------+
  • |
  • v
  • [Systemic End-Organ Manifestations]
  • 1. Massive Microvascular Endothelial Permeability
  • > Up to 35% intravascular volume lost in 10 minutes
  • 2. Systemic Arteriolar Vasodilation
  • > Profound distributive & hypovolaemic shock
  • 3. Bronchial Smooth Muscle Spasm
  • > Severe lower airway obstruction & wheeze
  • 4. Pharyngeal / Laryngeal Mucosal Edema
  • > Upper airway compromise & fatal asphyxiation
  • Mediators and Microvascular Leak

Histamine : Acts via H 1 H_1 H 1 ​ receptors to stimulate bronchial smooth muscle contraction, increase vascular permeability, and provoke sensory nerve activation (pruritus). Acts via H 2 H_2 H 2 ​ receptors to promote gastric acid secretion, enhance vascular permeability, and augment cardiac chronotropy and coronary vasodilation.

Cysteinyl Leukotrienes ( L T C 4 , L T D 4 , L T E 4 LTC_4, LTD_4, LTE_4 L T C 4 ​ , L T D 4 ​ , L T E 4 ​ ) : Previously known as "slow-reacting substance of anaphylaxis," leukotrienes are 1,000 times more potent than histamine in triggering sustained bronchoconstriction, airway mucous secretion, and vascular leakage.

Extravasation Dynamics : Widespread endothelial separation allows the rapid shift of up to 35 % 35\% 35% of effective circulating intravascular volume into the interstitial third space within the first 10 minutes of symptom onset. This produces a combined distributive and profound hypovolaemic shock state.

First-Line Pharmacotherapy: Intramuscular Adrenaline

Adrenaline (epinephrine) is the only evidence-based life-saving medication in anaphylaxis. It must be administered immediately upon clinical suspicion.

Pharmacodynamic Mechanisms

α 1 \alpha_1 α 1 ​ -adrenergic receptor stimulation : Induces potent peripheral vasoconstriction, reversing systemic vasodilation, increasing diastolic blood pressure, improving coronary perfusion, and dramatically reducing mucosal oedema in the larynx and upper airway.

β 1 \beta_1 β 1 ​ -adrenergic receptor stimulation : Increases myocardial contractility (positive inotropy) and heart rate (positive chronotropy), restoring stroke volume and cardiac output.

β 2 \beta_2 β 2 ​ -adrenergic receptor stimulation : Induces rapid bronchial smooth muscle relaxation (bronchodilation) and, critically, inhibits further mast cell and basophil degranulation by upregulating intracellular cyclic adenosine monophosphate (cAMP).

Exact Dosing and Administration Protocol

Parameter Specification

Formulation 1 : 1 , 000 1:1,000 1 : 1 , 000 concentration ( 1 mg/mL 1\text{ mg/mL} 1 mg/mL ) — NEVER use 1 : 10 , 000 1:10,000 1 : 10 , 000 for intramuscular injection

Exact Weight-Based Dose 10 micrograms/kg 10\text{ micrograms/kg} 10 micrograms/kg ( 0.01 mg/kg 0.01\text{ mg/kg} 0.01 mg/kg or 0.01 mL/kg 0.01\text{ mL/kg} 0.01 mL/kg of 1 : 1 , 000 1:1,000 1 : 1 , 000 solution)

  • Maximum Single Dose 0.5 mg 0.5\text{ mg} 0.5 mg ( 0.5 mL 0.5\text{ mL} 0.5 mL )
  • Route of Administration Strictly Intramuscular (IM)
  • Anatomical Site Anterolateral aspect of the middle third of the thigh (Vastus Lateralis)
  • Repeat Dosing Interval Repeat every 5 minutes if respiratory or circulatory symptoms fail to resolve
  • Auto-Injector Weight Brackets

When using fixed-dose pre-filled adrenaline auto-injectors (AAIs):

Infants < 7.5 kg <7.5\text{ kg} < 7.5 kg : Exact manual syringe draw ( 0.01 mL/kg 0.01\text{ mL/kg} 0.01 mL/kg ) is ideal; or 0.1 mg 0.1\text{ mg} 0.1 mg device where approved.

Children 7.5 kg to 25 − 30 kg 7.5\text{ kg to }25-30\text{ kg} 7.5 kg to 25 − 30 kg : 0.15 mg 0.15\text{ mg} 0.15 mg auto-injector (e.g., EpiPen Jr, Jext 150).

Children 25 − 30 kg to 50 kg 25-30\text{ kg to }50\text{ kg} 25 − 30 kg to 50 kg : 0.3 mg 0.3\text{ mg} 0.3 mg auto-injector (e.g., EpiPen, Jext 300).

Adolescents > 50 kg >50\text{ kg} > 50 kg and Adults : 0.3 to 0.5 mg 0.3\text{ to }0.5\text{ mg} 0.3 to 0.5 mg auto-injector (e.g., Emerade 500, EpiPen 300).

Vastus Lateralis versus Deltoid and Subcutaneous Routes

Intramuscular mid-thigh adrenaline is preferred. In the Simons 1998 paediatric pharmacokinetic study, mean time to peak plasma concentration was 8 ± 2 minutes with IM injection and 34 ± 14 minutes with subcutaneous injection . Separately, comparative studies support higher concentrations after thigh than deltoid injection. These findings support prompt IM delivery into the anterolateral mid-thigh.

Warning

There are no absolute contraindications to the administration of intramuscular adrenaline in a patient experiencing anaphylaxis. Fear of cardiovascular toxicity or benign transient side effects (tremor, palpitations, anxiety, pallor) must never delay immediate adrenaline delivery.

Patient Posture and the "Empty Ventricle Syndrome"

Patient positioning is a critical, frequently overlooked determinant of survival in anaphylaxis: [Patient with Severe Anaphylaxis Placed Abruptly Upright]

  • |
  • v
  • Massive Capillary Leakage & Arteriolar Vasodilation
  • |
  • v
  • Venous Blood Pools Heavily in Lower Extremities
  • |
  • v
  • Critical Reduction in Venous Return and Ventricular Filling
  • |
  • v
  • [The "Empty Ventricle Syndrome" / Cardiac Arrest]
  • Severely reduced preload and cardiac output
  • Ischaemic myocardial collapse
  • Immediate Pulseless Electrical Activity (PEA) Arrest
  • The Empty Ventricle Mechanism

Systemic vasodilation and rapid fluid extravasation reduce central venous filling. Sudden sitting, standing or walking can pool blood in the splanchnic and leg veins, sharply reducing venous return, cardiac output and myocardial perfusion. This severe preload loss—the “empty ventricle” mechanism—can precipitate collapse and PEA arrest.

Clinical Management Rules for Posture

Circulatory instability : Keep the patient flat, with legs raised if tolerated, to support venous return.

Unconscious but breathing normally, or vomiting : Use a lateral recovery position and protect the airway; monitor breathing continuously.

Predominant breathing difficulty : A supported semi-recumbent position may help breathing, with legs supported where possible. Avoid sudden postural change. Do not allow standing or walking during the acute reaction , including transfers.

Second-Line Adjunctive Therapies: What They Do and Do Not Do

Adjunctive medications play a secondary, supportive role and must never be administered prior to or in place of adrenaline:

Medication Dosing Clinical Role Critical Limitation

High-Flow Oxygen 10 to 15 L/min 10\text{ to }15\text{ L/min} 10 to 15 L/min via non-rebreather mask Delivers high inspired O 2 O_2 O 2 ​ to compensate for ventilation-perfusion mismatch and lactic acidosis Does not reverse mucosal swelling or bronchospasm

Isotonic Crystalloids 10 to 20 mL/kg 10\text{ to }20\text{ mL/kg} 10 to 20 mL/kg balanced crystalloid rapid IV/IO bolus Replaces massive intravascular fluid extravasation in distributive/hypovolaemic shock Fluid boluses alone will leak through permeable endothelium without concurrent adrenaline

Inhaled β 2 \beta_2 β 2 ​ -Agonists (Salbutamol) 2.5 to 5 mg 2.5\text{ to }5\text{ mg} 2.5 to 5 mg nebulized with oxygen Relieves persistent lower airway bronchospasm and wheeze Has zero effect on laryngeal oedema, upper airway obstruction, or cardiovascular shock

Nebulized Adrenaline 5 mL 5\text{ mL} 5 mL of 1 : 1 , 000 1:1,000 1 : 1 , 000 undiluted solution Provides local vasoconstriction to temporarily reduce laryngeal oedema in severe stridor Adjunct to IM adrenaline; preparation for emergency intubation must continue

H 1 H_1 H 1 ​ -Antihistamines (Cetirizine, Chlorphenamine) Chlorphenamine 0.2 mg/kg IV/IM 0.2\text{ mg/kg IV/IM} 0.2 mg/kg IV/IM or Cetirizine orally Relieves cutaneous symptoms: urticaria, pruritus, and facial flushing Zero effect on airway compromise or cardiovascular shock; sedating agents obscure mental status

Systemic Corticosteroids (Methylprednisolone, Hydrocortisone) Methylprednisolone 1 to 2 mg/kg IV 1\text{ to }2\text{ mg/kg IV} 1 to 2 mg/kg IV or Hydrocortisone 4 mg/kg IV 4\text{ mg/kg IV} 4 mg/kg IV Modulates late-phase inflammatory mediator transcription; historically used for biphasic reactions Delayed onset of action ( 4 to 6 hours 4\text{ to }6\text{ hours} 4 to 6 hours ); meta-analyses show questionable clinical efficacy

Note

Antihistamines and corticosteroids are third-line supportive therapies . Administering antihistamines first while withholding or delaying adrenaline is the leading cause of preventable paediatric anaphylaxis fatalities.

Management of Refractory Anaphylaxis

Refractory anaphylaxis is defined as persistent respiratory compromise or circulatory shock despite two or more properly administered doses of intramuscular adrenaline accompanied by aggressive fluid resuscitation.

Continuous Intravenous Adrenaline Infusion

After two appropriate IM doses with persistent respiratory/circulatory compromise, seek urgent expert help and start a titrated IV adrenaline infusion in a suitably monitored setting. Continue IM adrenaline every 5 minutes while the infusion is organised or if it cannot safely be given.

Infusion Dosing : Start at 0.05 to 0.1 micrograms/kg/min 0.05\text{ to }0.1\text{ micrograms/kg/min} 0.05 to 0.1 micrograms/kg/min , titrated every 2 to 3 minutes by increments of 0.02 to 0.05 mcg/kg/min 0.02\text{ to }0.05\text{ mcg/kg/min} 0.02 to 0.05 mcg/kg/min based on continuous arterial blood pressure, heart rate, and tissue perfusion (titrated up to 1.0 mcg/kg/min 1.0\text{ mcg/kg/min} 1.0 mcg/kg/min in severe collapse).

Monitoring : A trained clinician must supervise continuous ECG/SpO2, frequent BP measurement (non-invasive at least every 5 minutes until an arterial line is established) and a dedicated infusion-pump line. Check the infusion site and titrate to response. Obtain critical-care support and invasive monitoring when practicable; do not delay treatment for PICU transfer or arterial access.

The Patient on Beta-Blocker Therapy: Glucagon

Patients receiving chronic beta-adrenergic antagonist therapy (e.g., propranolol for migraines, infantile haemangiomas, or arrhythmias) exhibit marked resistance to adrenaline because adrenergic receptors are competitive blocked. These patients develop profound, intractable bradycardia and hypotension.

Management : Administer Intravenous Glucagon :

Bolus dose: 20 to 30 micrograms/kg 20\text{ to }30\text{ micrograms/kg} 20 to 30 micrograms/kg (maximum single dose 1 mg 1\text{ mg} 1 mg ) infused over 5 minutes.

Continuous infusion: Follow with 5 to 15 micrograms/min 5\text{ to }15\text{ micrograms/min} 5 to 15 micrograms/min titrated to response.

Mechanism : Glucagon bypasses the blocked beta-adrenergic receptor by directly activating adenylate cyclase via specific non-adrenergic G-protein-coupled receptors, driving intracellular cyclic AMP production and restoring myocardial inotropy and chronotropy.

Biphasic Reactions and Inpatient Observation Protocols

A biphasic anaphylactic reaction is defined as the recurrence of clinical anaphylaxis symptoms within 1 to 72 hours (most commonly within 4 to 12 hours ) after the complete clinical resolution of the initial event, occurring without any re-exposure to the trigger. Biphasic reactions occur in approximately 5 % to 20 % 5\%\text{ to }20\% 5% to 20% of paediatric presentations.

Risk Factors for Biphasic Anaphylaxis

Severe initial presentation (profound hypotension or respiratory arrest).

Requirement for more than one dose of adrenaline to control initial symptoms.

Delay in receiving the first dose of adrenaline ( > 30 to 60 minutes >30\text{ to }60\text{ minutes} > 30 to 60 minutes after symptom onset).

Wide pulse pressure at initial presentation.

Co-existing diagnosis of poorly controlled asthma.

Observation According to Risk and Local Protocol

EAACI 2021 : Observe patients with respiratory compromise for at least 6–8 hours ; after hypotension, observe for at least 12–24 hours .

RCUK 2021 : Use risk-stratified observation from symptom resolution. Selected patients with a rapid, complete response to one early IM dose, two auto-injectors with training, and adequate supervision may leave after 2 hours . Observe at least 6 hours after two IM doses or a previous biphasic reaction, and at least 12 hours after a severe reaction requiring more than two doses, severe asthma/respiratory compromise, or other ongoing risk. Persistent instability requiring an infusion needs critical care.

Comprehensive Discharge Protocol

Prior to discharging a child who has stabilized following an anaphylactic event, the multidisciplinary clinical team must verify the five pillars of paediatric allergy discharge :

Two Adrenaline Auto-Injectors (The "Rule of Two") : Prescribe and dispense two pre-filled adrenaline auto-injectors calibrated to the child's exact weight. (Two devices are mandatory because up to 20% of patients require a second dose before emergency medical services arrive).

Practical Training : Provide direct hands-on training to both the parents/caregivers and the child (if developmentally capable) using an unmedicated trainer device , ensuring proper technique and needle disposal.

Written Anaphylaxis Action Plan : Supply a personalized, written Paediatric Anaphylaxis Emergency Action Plan detailing symptoms, trigger avoidance, and step-by-step instructions for auto-injector delivery for home, school, and childcare environments.

Trigger Avoidance Education : Offer clear dietary or environmental elimination guidance.

Subspecialty Allergy Referral : Arrange a formal, urgent outpatient appointment with a paediatric allergy specialist for diagnostic skin prick testing, serum-specific IgE quantification, component-resolved diagnostics, and consideration of allergen-specific immunotherapy (e.g., venom subcutaneous immunotherapy or peanut oral immunotherapy).